YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorWest China Hospital
About this trial
This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced hepatobiliary and pancreatic malignancies.
Eligibility criteria
Qualifiers
Voluntarily sign the informed consent form, and be able to understand and agree to comply with the study procedures and visits as specified in the protocol.
Age: 18 to 75 years old, male or female.
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;
Platelet count (PLT) ≥ 75 × 10⁹/L;
Disqualifiers
Presence of extensive peritoneal metastasis or intestinal obstruction.
Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
Known allergy to any component of the investigational drug (e.g., lipid nanoparticles, RNA carrier) or to drugs of the same class.
Prior receipt of vaccine therapy.
Trial design
Treatments tested in this trial
- YMN-136 vaccine
Treatment groups
9 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov